The Latest Cardiac and Vascular News
Proven medical device executive brings experience building thrombectomy businesses and guiding product strategy to support Vesalio’s continued growth DALLAS, Oct. 15, 2026 /PRNewswire/ — Vesalio, a global leader in vascular intervention, announces the appointment of Daniel Davis to its…
Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year. SAN FRANCISCO, Oct. 15, 2026 /PRNewswire/ — Sirona Medical, Inc. (“Sirona”), the market leader in cloud-native radiology software, today announced $40 million in Series D…
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec
Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia’s ongoing ACOUSTIC‑1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch LOS ANGELES, Oct. 13, 2026 /PRNewswire/ –…
DALLAS, Oct. 13, 2026 /PRNewswire/ — Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, has announced its participation in two upcoming investor conferences: Goldman Sachs Healthcare Private Company Conference — Andy Doraiswamy…
Southern California physician leader returns to Long Beach and Orange County, where his medical career began, to help advance cardiovascular care across MemorialCare. FOUNTAIN VALLEY, Calif., Oct. 12, 2026 /PRNewswire/ — MemorialCare—a leading nonprofit integrated health system in…
SAN DIEGO, Oct. 8, 2026 /PRNewswire/ — Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase…
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on N
Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care. iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect’s growth and expand customer access. Transaction is expected to enhance iRhythm’s […]
